Arcutis Biotherapeutics (ARQT) News Today $14.55 +0.21 (+1.46%) Closing price 04:00 PM EasternExtended Trading$14.54 -0.02 (-0.10%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARQT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period GW&K Investment Management LLC Sells 31,873 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)July 22 at 8:25 AM | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.4% - Here's What HappenedJuly 19 at 5:01 PM | marketbeat.comJackson Creek Investment Advisors LLC Decreases Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)July 18, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stake Decreased by Jennison Associates LLCJuly 18, 2025 | marketbeat.comPatrick Burnett Sells 23,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockJuly 16, 2025 | americanbankingnews.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 5,750 Shares of StockJuly 15, 2025 | americanbankingnews.comPatrick Burnett Sells 5,750 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockJuly 15, 2025 | insidertrades.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 5,750 Shares of StockJuly 14, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 23,000 SharesJuly 14, 2025 | marketbeat.comBrokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target at $18.80July 13, 2025 | americanbankingnews.comArcutis Biotherapeutics Stock Scores RS Rating UpgradeJuly 12, 2025 | msn.comArcutis Biotherapeutics Earns Relative Strength Rating Upgrade; Hits Key BenchmarkJuly 11, 2025 | msn.comArcutis Biotherapeutics Shows Rising Relative Price Performance; Still Shy Of Key ThresholdJuly 10, 2025 | msn.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 10, 2025 | marketbeat.comArcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic DermatitisJuly 9, 2025 | msn.comPenserra Capital Management LLC Makes New Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)July 8, 2025 | marketbeat.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.com26,520 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Purchased by Perpetual LtdJune 29, 2025 | marketbeat.comArcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis DirectionJune 27, 2025 | seekingalpha.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 4.2% - Should You Sell?June 27, 2025 | marketbeat.comArcutis Biotherapeutics Clears Key Benchmark, Hitting 80-Plus RS RatingJune 27, 2025 | msn.comArcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic DermatitisJune 26, 2025 | globenewswire.comArcutis Biotherapeutics: Another Approval Under Their BeltJune 25, 2025 | seekingalpha.comARQT Arcutis Biotherapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comArcutis Biotherapeutics Scores Relative Strength Rating Upgrade; Hits Key ThresholdJune 24, 2025 | msn.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Howard G. Welgus Sells 10,139 SharesJune 20, 2025 | marketbeat.comStocks With Rising Relative Price Strength: Arcutis BiotherapeuticsJune 20, 2025 | msn.comSilverleafe Capital Partners LLC Acquires New Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)June 19, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Patrick J. Heron Purchases 2,646 SharesJune 18, 2025 | insidertrades.comPatrick J. Heron Buys 2,646 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockJune 17, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Takes $291,000 Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)June 16, 2025 | marketbeat.comArcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 TrialsJune 15, 2025 | msn.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Rating of "Moderate Buy" from AnalystsJune 15, 2025 | marketbeat.comArcutis: Out Of The Woods, Ready For CommercializationJune 12, 2025 | seekingalpha.comArcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic DermatitisJune 10, 2025 | finance.yahoo.comArcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic DermatitisJune 10, 2025 | globenewswire.comArcutis Biotherapeutics Presents Positive Phase 3 INTEGUMENT-OLE Study Data on ZORYVE Cream for Atopic Dermatitis at RAD Conference 2025June 8, 2025 | nasdaq.comArcutis Biotherapeutics Insider Trading Activity | NASDAQ:ARQT | BenzingaJune 7, 2025 | benzinga.comInsider Buying: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Buys 1,890 Shares of StockJune 7, 2025 | insidertrades.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comPatrick J. Heron Buys 1,890 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockJune 6, 2025 | marketbeat.comArcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis ConferenceJune 6, 2025 | globenewswire.comTwo Sigma Investments LP Cuts Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)June 5, 2025 | marketbeat.comArcutis Biotherapeutics: Navigating Commercialization With Promising UpsideJune 5, 2025 | seekingalpha.comNuveen Asset Management LLC Has $5.11 Million Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)June 1, 2025 | marketbeat.comAmeriprise Financial Inc. Acquires 50,662 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)June 1, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Masaru Matsuda Sells 1,800 SharesMay 31, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 5% - Time to Sell?May 31, 2025 | marketbeat.comSquarepoint Ops LLC Has $1.69 Million Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)May 31, 2025 | marketbeat.comArcutis to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceMay 29, 2025 | globenewswire.com Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Media Mentions By Week ARQT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼1.140.59▲Average Medical News Sentiment ARQT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼57▲ARQT Articles Average Week Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ELAN News Today RGC News Today LEGN News Today RVMD News Today GRFS News Today TGTX News Today NUVL News Today LNTH News Today RYTM News Today AXSM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
